The Food and Drug Administration (FDA) has approved the first newborn screening tool for four rare lysosomal storage disorders (LSDs), rare inherited metabolic disorders that if not detected and treated in a timely manner can cause organ damage, neurological disability or death. The test, which will be marketed as the Seeker System, is designed to detect the LSDs Mucopolysaccharidosis Type I (MPS I) Pompe, Gaucher and Fabry. The conditions occur in about 1 in 1,500 to 1 in 185,000 newborns and children, depending on the disorder. Several states currently mandate LSD screening in all newborns, such as Arizona, Illinois, Kentucky, ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.